Inogen Inc (INGN) Shares Bought by Flagship Harbor Advisors LLC

Flagship Harbor Advisors LLC lifted its position in shares of Inogen Inc (NASDAQ:INGN) by 1,090.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 655 shares of the medical technology company’s stock after acquiring an additional 600 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in Inogen were worth $157,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in INGN. OppenheimerFunds Inc. raised its position in shares of Inogen by 40.3% during the 2nd quarter. OppenheimerFunds Inc. now owns 286,147 shares of the medical technology company’s stock worth $53,318,000 after purchasing an additional 82,164 shares during the last quarter. WINTON GROUP Ltd raised its position in shares of Inogen by 382.8% during the 2nd quarter. WINTON GROUP Ltd now owns 67,012 shares of the medical technology company’s stock worth $12,486,000 after purchasing an additional 53,133 shares during the last quarter. Thompson Siegel & Walmsley LLC acquired a new position in shares of Inogen during the 2nd quarter worth approximately $186,000. BlackRock Inc. raised its position in shares of Inogen by 7.2% during the 2nd quarter. BlackRock Inc. now owns 2,591,083 shares of the medical technology company’s stock worth $482,796,000 after purchasing an additional 173,035 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Inogen by 4.6% during the 2nd quarter. California Public Employees Retirement System now owns 31,149 shares of the medical technology company’s stock worth $5,804,000 after purchasing an additional 1,376 shares during the last quarter. 96.67% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts recently issued reports on the company. ValuEngine downgraded Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $280.00 price objective (down from $296.00) on shares of Inogen in a research report on Wednesday. BidaskClub downgraded Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, October 27th. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Thursday, September 27th. Finally, Piper Jaffray Companies lifted their price objective on Inogen from $245.00 to $290.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Inogen has a consensus rating of “Buy” and an average target price of $244.67.

Shares of INGN opened at $148.51 on Friday. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of 68.58, a price-to-earnings-growth ratio of 2.89 and a beta of 1.56. Inogen Inc has a fifty-two week low of $111.49 and a fifty-two week high of $287.79.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.21. The company had revenue of $95.29 million during the quarter, compared to the consensus estimate of $90.94 million. Inogen had a return on equity of 18.91% and a net margin of 12.28%. Inogen’s revenue was up 38.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.33 EPS. Equities research analysts anticipate that Inogen Inc will post 2.1 earnings per share for the current fiscal year.

In other news, Director Raymond Huggenberger sold 10,500 shares of the company’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $228.63, for a total transaction of $2,400,615.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Heath Lukatch sold 500 shares of the company’s stock in a transaction on Tuesday, November 6th. The stock was sold at an average price of $193.97, for a total value of $96,985.00. Following the sale, the director now owns 1,489 shares of the company’s stock, valued at $288,821.33. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,000 shares of company stock valued at $11,098,610. Insiders own 5.29% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Inogen Inc (INGN) Shares Bought by Flagship Harbor Advisors LLC” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2018/11/11/inogen-inc-ingn-shares-bought-by-flagship-harbor-advisors-llc.html.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Article: How to invest in a bear market

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply